Management of Tumor- and Non-Tumor-related Aorto-esophageal and Aorto-bronchial fistulas.

Please login or register to bookmark this article
Bookmark this %label%

This study aims to review and compare the clinical presentation, management, and outcome in patients with tumor-related (TR) and non-tumor-related (NTR) aorto-esophageal (AEF) and aorto-bronchial fistulas (ABF) with particular focus on the thoracic endovascular aortic repair.We retrospectively reviewed a series of 16 consecutive patients with TR (n=8) and NTR (n=8), ABF (n=6), and AEF (n=10) admitted to our hospital from 2011 to 2019.The median age was 62 years (range 46-81), with 11 men. The most common predisposing factor was esophageal or gastric cardia cancer (n=6), followed by open repair of the thoracic aorta (n=5). Endoluminal vacuum therapy (Endo-SPONGE®) accounted for three cases of AEFs. TEVAR was applied in 13 patients (4 with ABFs and 9 with AEFs). The primary technical success of the TEVARs was 100%. One patient (8%) was complicated with postoperative middle cerebral artery syndrome and left-sided hemiparesis. The respective in-hospital-, 6-month-, and 1-year-mortality rates were 0% (n = 0), 25% (n = 2) and 25% (n = 2) for the NTR group, and 63% (n = 5), 88% (n = 7), 100% (n = 8) for the TR group. After a mean period of 13 months, five (31%) patients were still alive, and one patient lost to follow-up after 11 months. The survivors (n=5) had all non-tumor-related ABF. Progression of underlying cancer and hemodynamic shock were the most common causes of death.TEVAR represents a reliable option in the treatment of NTR ABFs. In the cases of TR fistulas and NTR AEFs, TEVAR should be applied more selectively. The associated mortality remains very high.

View the full article @ Annals of vascular surgery
Get PDF with LibKey